Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
corbuspharma.com
Company Research
Source: GlobeNewswire
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701 to treat metastatic cervical cancerCRB 913 SAD/MAD obesity study expected to start in March 2025$149m of cash & investments as of December 31,2024 and cash runway expected through Q3 2027 NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2024. “During the fourth quarter and into 2025, we made significant progress across our pipeline. Both of our oncology programs (CRB-701 and CRB-601) have been advancing in the clinic and our obesity program (CRB-913) is on schedule for first in human dosing later this month. We were encouraged by the data for CRB-701 from our study in Western patients t
Show less
Read more
Impact Snapshot
Event Time:
CRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRBP alerts
High impacting Corbus Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CRBP
News
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript [Seeking Alpha]Seeking Alpha
- Corbus Pharmaceuticals (NASDAQ:CRBP) had its price target lowered by analysts at Royal Bank Of Canada from $55.00 to $53.00. They now have an "outperform" rating on the stock.MarketBeat
- Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewswire
- Corbus Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window [Seeking Alpha]Seeking Alpha
CRBP
Earnings
- 11/12/25 - Miss
CRBP
Sec Filings
- 12/18/25 - Form 8-K
- 12/15/25 - Form SCHEDULE
- 12/15/25 - Form 4
- CRBP's page on the SEC website